Hedge fund Farallon Capital Management established a new position in Lantheus Holdings (LNTH), a radiopharmaceutical company, according to its latest quarterly disclosure. The filing reveals Farallon acquired 5.58 million shares, valued at approximately $423.51 million. This new holding represents a 2.41% weight in the investment firm's reported portfolio.
This disclosure reflects Farallon's holdings as of March 31, 2026, and was made public on August 14. Lantheus specializes in products that help clinicians diagnose and treat diseases, particularly in oncology and cardiology. During the first quarter, Lantheus reported revenue of $377.3 million and received FDA approval for its PYLARIFY TruVu imaging agent.